Cargando…
Seniors with Parkinson's Disease: Initial Medical Treatment
Parkinson's disease most often presents after age 60, and patients in this age group are best managed with levodopa therapy as the primary treatment modality. Unlike young-onset parkinsonism (onset <age 40), this older age group is much less prone to subsequent development of levodopa respon...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Korean Neurological Association
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024520/ https://www.ncbi.nlm.nih.gov/pubmed/21264196 http://dx.doi.org/10.3988/jcn.2010.6.4.159 |
_version_ | 1782196801345945600 |
---|---|
author | Ahlskog, J. Eric |
author_facet | Ahlskog, J. Eric |
author_sort | Ahlskog, J. Eric |
collection | PubMed |
description | Parkinson's disease most often presents after age 60, and patients in this age group are best managed with levodopa therapy as the primary treatment modality. Unlike young-onset parkinsonism (onset <age 40), this older age group is much less prone to subsequent development of levodopa responsive instability (dyskinesias, fluctuations). When these problems do occur in seniors, they usually can be managed by medication adjustments. The treatment goal is to keep patients active and engaged; levodopa dosage should be guided by the patients' responses and not arbitrarily limited to low doses, which may compromise patients' lives. |
format | Text |
id | pubmed-3024520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Korean Neurological Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-30245202011-01-24 Seniors with Parkinson's Disease: Initial Medical Treatment Ahlskog, J. Eric J Clin Neurol Review Parkinson's disease most often presents after age 60, and patients in this age group are best managed with levodopa therapy as the primary treatment modality. Unlike young-onset parkinsonism (onset <age 40), this older age group is much less prone to subsequent development of levodopa responsive instability (dyskinesias, fluctuations). When these problems do occur in seniors, they usually can be managed by medication adjustments. The treatment goal is to keep patients active and engaged; levodopa dosage should be guided by the patients' responses and not arbitrarily limited to low doses, which may compromise patients' lives. Korean Neurological Association 2010-12 2010-12-31 /pmc/articles/PMC3024520/ /pubmed/21264196 http://dx.doi.org/10.3988/jcn.2010.6.4.159 Text en Copyright © 2010 Korean Neurological Association |
spellingShingle | Review Ahlskog, J. Eric Seniors with Parkinson's Disease: Initial Medical Treatment |
title | Seniors with Parkinson's Disease: Initial Medical Treatment |
title_full | Seniors with Parkinson's Disease: Initial Medical Treatment |
title_fullStr | Seniors with Parkinson's Disease: Initial Medical Treatment |
title_full_unstemmed | Seniors with Parkinson's Disease: Initial Medical Treatment |
title_short | Seniors with Parkinson's Disease: Initial Medical Treatment |
title_sort | seniors with parkinson's disease: initial medical treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024520/ https://www.ncbi.nlm.nih.gov/pubmed/21264196 http://dx.doi.org/10.3988/jcn.2010.6.4.159 |
work_keys_str_mv | AT ahlskogjeric seniorswithparkinsonsdiseaseinitialmedicaltreatment |